GeoVax Labs 과거 수익 실적

과거 기준 확인 0/6

GeoVax Labs의 수입은 연평균 -46.1%의 비율로 감소해 온 반면, Biotechs 산업은 수입이 연평균 19%의 비율로 증가했습니다. 매출은 연평균 52.6%의 비율로 감소해 왔습니다.

주요 정보

-46.1%

수익 성장률

51.3%

EPS 성장률

Biotechs 산업 성장	17.0%
매출 성장률	-52.6%
자기자본 수익률	n/a
순이익	-8,951.6%
최근 수익 업데이트	30 Jun 2024

최근 과거 실적 업데이트

Recent updates

GeoVax: A Legitimate COVID-19 Phase 2 Vaccine Candidate Trading At Only A $25 Million Valuation

Dec 27

We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth

Nov 27

GeoVax: Expands Immuno-Oncology Pipeline With Clinical-Stage Program

Oct 03

We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth

Aug 14

Did Business Growth Power GeoVax Labs' (NASDAQ:GOVX) Share Price Gain of 111%?

Feb 18

GeoVax soars on NIAID grant for COVID-19 vaccine candidate

Jan 11

수익 및 비용 분석

GeoVax Labs 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NasdaqCM:GOVX 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용
30 Jun 24	0	-27	6
31 Mar 24	0	-28	6
31 Dec 23	0	-26	6
30 Sep 23	0	-24	6
30 Jun 23	0	-19	6
31 Mar 23	0	-16	5
31 Dec 22	0	-14	5
30 Sep 22	0	-22	4
30 Jun 22	0	-20	4
31 Mar 22	0	-19	4
31 Dec 21	0	-19	4
30 Sep 21	0	-6	3
30 Jun 21	1	-5	3
31 Mar 21	1	-4	3
31 Dec 20	2	-3	2
30 Sep 20	2	-2	2
30 Jun 20	2	-2	2
31 Mar 20	2	-2	2
31 Dec 19	1	-2	2
30 Sep 19	1	-2	2
30 Jun 19	1	-3	2
31 Mar 19	1	-3	2
31 Dec 18	1	-3	2
30 Sep 18	1	-2	1
30 Jun 18	1	-2	1
31 Mar 18	1	-2	1
31 Dec 17	1	-2	1
30 Sep 17	1	-3	2
30 Jun 17	1	-2	2
31 Mar 17	1	-3	2
31 Dec 16	1	-3	2
30 Sep 16	1	-3	2
30 Jun 16	0	-3	2
31 Mar 16	0	-3	2
31 Dec 15	0	-3	1
30 Sep 15	0	-3	2
30 Jun 15	1	-3	2
31 Mar 15	1	-3	2
31 Dec 14	1	-3	2
30 Sep 14	1	-3	2
30 Jun 14	2	-2	1
31 Mar 14	2	-2	2
31 Dec 13	2	-2	2

양질의 수익: GOVX 은(는) 현재 수익성이 없습니다.

이익 마진 증가: GOVX 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: GOVX 은(는) 수익성이 없으며 지난 5년 동안 연간 46.1% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 GOVX 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: GOVX 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( -2.3% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: GOVX 의 부채가 자산을 초과하므로 자기자본수익률을 계산하기 어렵습니다.

GeoVax Labs 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

GeoVax Labs, Inc. to Report Q2, 2024 Results on Aug 06, 2024

GeoVax Labs, Inc. to Report Q1, 2024 Results on May 14, 2024

GeoVax Labs, Inc. to Report Q4, 2023 Results on Feb 29, 2024

GeoVax Labs, Inc. to Report Q3, 2023 Results on Nov 08, 2023

GeoVax Labs, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

GeoVax Labs, Inc. has filed a Follow-on Equity Offering in the amount of $4.486846 million.

GeoVax Labs, Inc. has filed a Follow-on Equity Offering in the amount of $5.000001 million.

GeoVax Labs, Inc. has filed a Follow-on Equity Offering in the amount of $8.499997 million.

GeoVax Labs, Inc. has filed a Follow-on Equity Offering in the amount of $8.499997 million.

GeoVax Labs, Inc. has filed a Follow-on Equity Offering in the amount of $8.5 million.

Geovax Labs, Inc. Announces Phase 2 Plans for Gedeptin®? Cancer Therapy Following Clinical Advisory Committee Review

GeoVax Labs, Inc. to Report Q2, 2024 Results on Aug 06, 2024

GeoVax Labs Receives Letter from Nasdaq Due to Failure to Comply with Nasdaq’s Shareholder Approval Requirements Set Forth in Nasdaq Listing Rule 5635(d)

GeoVax Labs Receives a Notice from Nasdaq Regarding Non-Compliance with Minimum $2.5 Million Stockholders’ Equity Requirement Pursuant to Nasdaq Listing Rule 5550(b)(1)

Price target increased by 14% to US$120

GeoVax Labs, Inc. to Report Q1, 2024 Results on May 14, 2024

GeoVax Labs, Inc., Annual General Meeting, May 23, 2024

GeoVax Labs, Inc. to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress

GeoVax Labs, Inc. Achieves Milestone in Transition to Commercially Validated Manufacturing System

New minor risk - Shareholder dilution

Price target increased by 14% to US$120

GeoVax Labs, Inc. to Report Q4, 2023 Results on Feb 29, 2024

GeoVax Labs Regains Compliance with Nasdaq Minimum Bid Requirement

Geovax Reports Positive Interim Data from Phase 2 Clinical Trial of Geo-Cm04s1 as A Universal Covid-19 Vaccine Booster

GeoVax Announces 1 for 15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement

Geovax Appoints Marc Pipas as Executive Medical Director, Oncology

New major risk - Market cap size

GeoVax Labs Receives a Notice from the Nasdaq Stock Market

Geovax Labs, Inc. Announces the Presentation of Preclinical Vaccine Efficacy Data for GEO-CM02

New major risk - Revenue and earnings growth

GeoVax Labs, Inc. to Report Q3, 2023 Results on Nov 08, 2023

GeoVax Labs, Inc. Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine

Geovax Labs, Inc. Next-Generation Covid-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients

GeoVax Labs, Inc. Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster

New major risk - Financial position

GeoVax Labs, Inc. Announces First Patients Vaccinated in Phase 2 Clinical Trial of Covid-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

GeoVax Labs, Inc. to Report Q2, 2023 Results on Aug 09, 2023

GeoVax Labs, Inc. Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

GeoVax Labs, Inc., Annual General Meeting, Aug 01, 2023

GeoVax Labs, Inc. Announces Next-Generation COVID-19 Vaccine Data to Be Presented At Two Upcoming Scientific Meetings

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers

Geovax Labs, Inc. Appoints Valerie Montgomery Rice as Special Advisor to the Chairman/CEO and Board of Directors

GeoVax Labs Receives Non-Compliance Notice From Nasdaq

GeoVax Labs, Inc. Appoints Jayne Morgan to Board of Directors

Price target decreased to US$5.50

Third quarter 2022 earnings released: US$0.17 loss per share (vs US$0.31 loss in 3Q 2021)

High number of new directors

GeoVax Labs, Inc. to Report Q3, 2022 Results on Nov 09, 2022

We Think GeoVax Labs (NASDAQ:GOVX) Needs To Drive Business Growth Carefully

Geovax Announces Appointment of Nicole Lemerond to Its Board of Directors

GeoVax: Possible Vaccine Advancements In 2 Big Indications

Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.21 loss in 2Q 2021)

GeoVax adds 16% as journal publishes animal study on ebolavirus vaccine

GeoVax Labs, Inc. to Report Q2, 2022 Results on Aug 03, 2022

GeoVax Labs, Inc., Annual General Meeting, Aug 03, 2022

Companies Like GeoVax Labs (NASDAQ:GOVX) Could Be Quite Risky

First quarter 2022 earnings released: US$0.34 loss per share (vs US$0.29 loss in 1Q 2021)

Insufficient new directors

GeoVax Labs, Inc. to Report Q1, 2022 Results on Apr 27, 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Geovax Labs, Inc. Announces Management Appointments

GeoVax Labs, Inc. to Report Fiscal Year 2021 Results on Mar 09, 2022

GeoVax Labs, Inc. announced that it has received $9.999998 million in funding

GeoVax: A Legitimate COVID-19 Phase 2 Vaccine Candidate Trading At Only A $25 Million Valuation

GeoVax Labs, Inc. Announces Initiation of Phase 2 Clinical Trial for Covid-19 Vaccine Booster

GeoVax Labs, Inc. Presents Hemorrhagic Fever Vaccine Data at World Vaccine & Immunotherapy Congress

We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth

Third quarter 2021 earnings released: US$0.31 loss per share (vs US$0.73 loss in 3Q 2020)

GeoVax: Expands Immuno-Oncology Pipeline With Clinical-Stage Program

Geovax Presents Covid-19 Vaccine Data At the European Society of Medicine (Esmed) General Assembly

We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth

Second quarter 2021 earnings released: US$0.21 loss per share (vs US$0.66 loss in 2Q 2020)

GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting